Pharma Pulse 1/8/25: Local Pharmacies and DCTs, New Therapies on the Horizon for Fatty Liver Disease & more

Local Pharmacies and Decentralized Clinical Trials

It’s become increasingly clear that a lack of diversity in clinical trials is a major issue for the pharmaceutical industry. While the problem has been identified, the industry is still struggling to find solutions. Shelli Pavone, president and co-founder of Inlightened, spoke with Pharmaceutical Executive about this issue and the ongoing methods to address it.

ASHP Midyear: New Therapies Are on the Horizon for Fatty Liver Disease, But Access Challenges Remain

New medications like GLP-1 agonists and resmiterone show promise in reversing fatty liver disease and preventing progression.

WuXi Bio to Sell Vaccine Facility to Merck for $500 Million

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.

Grove Secures $4.9 Million to Transform Clinical Trials with Agentic AI

Grove AI has announced a $4.9 million seed fundraise led by A*, with participation from Afore Capital, LifeX Ventures, Pear VC, Upfront Ventures, and industry-leading angels. This investment will allow Grove to continue scaling its team and product to redefine clinical trials from siloed operations into participant-centered ecosystems driven by real-time data.

Association for Prescription Psychedelics on LinkedIn

In a new interview with Pharmaceutical Commerce Magazine, Jon Kostas lays out our core goals and priorities. We’ll serve as a trusted voice for prescription psychedelic medicines and advocate for the safe and effective development of these potentially transformative treatments. By following the medical model, we can help eligible patients across the country access prescription psychedelic medicines to treat a wide range of challenging mental and physical health conditions.

https://lnkd.in/eB_pkv53

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs